152 related articles for article (PubMed ID: 12871163)
1. Molecular diversity of hydroxamic acids: part II. Potential therapeutic applications.
Lou B; Yang K
Mini Rev Med Chem; 2003 Sep; 3(6):609-20. PubMed ID: 12871163
[TBL] [Abstract][Full Text] [Related]
2. Conversion of potent MMP inhibitors into selective TACE inhibitors.
Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
[TBL] [Abstract][Full Text] [Related]
3. Hydroxamic acids as pharmacological agents.
Muri EM; Nieto MJ; Sindelar RD; Williamson JS
Curr Med Chem; 2002 Sep; 9(17):1631-53. PubMed ID: 12171558
[TBL] [Abstract][Full Text] [Related]
4. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
Bieliauskas AV; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359
[TBL] [Abstract][Full Text] [Related]
5. Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
Antczak C; Shum D; Bassit B; Frattini MG; Li Y; de Stanchina E; Scheinberg DA; Djaballah H
Bioorg Med Chem Lett; 2011 Aug; 21(15):4528-32. PubMed ID: 21719286
[TBL] [Abstract][Full Text] [Related]
6. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.
Dai Y; Guo Y; Guo J; Pease LJ; Li J; Marcotte PA; Glaser KB; Tapang P; Albert DH; Richardson PL; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2003 Jun; 13(11):1897-901. PubMed ID: 12749893
[TBL] [Abstract][Full Text] [Related]
7. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
[TBL] [Abstract][Full Text] [Related]
8. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Gimsing P
Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
[TBL] [Abstract][Full Text] [Related]
9. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Nam NH; Huong TL; Dung do TM; Dung PT; Oanh DT; Quyen D; Thao le T; Park SH; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB
Eur J Med Chem; 2013; 70():477-86. PubMed ID: 24185378
[TBL] [Abstract][Full Text] [Related]
10. Hydroxamic acid hybrids as the potential anticancer agents: An Overview.
Liu W; Liang Y; Si X
Eur J Med Chem; 2020 Nov; 205():112679. PubMed ID: 32791404
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
12. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
14. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
Charrier C; Bertrand P; Gesson JP; Roche J
Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
[TBL] [Abstract][Full Text] [Related]
16. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium.
Balakrishnan A; Patel B; Sieber SA; Chen D; Pachikara N; Zhong G; Cravatt BF; Fan H
J Biol Chem; 2006 Jun; 281(24):16691-9. PubMed ID: 16565079
[TBL] [Abstract][Full Text] [Related]
17. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: the Abbott experience.
Curtin M; Glaser K
Curr Med Chem; 2003 Nov; 10(22):2373-92. PubMed ID: 14529480
[TBL] [Abstract][Full Text] [Related]
20. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Seo SY
Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
